• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nexstim

9.80 EUR

-0.31 %

5,653 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
-0.31 %
+8.89 %
+8.17 %
-30.74 %
-30.99 %
-32.65 %
+184.06 %
+131.68 %
-98.38 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
79.13M EUR
Turnover
38.46K EUR
P/E (adj.) (26e)
78.46
EV/EBIT (adj.) (26e)
63.68
P/B (26e)
7.74
EV/S (26e)
6.05
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
11.00 EUR
Updated
14.05.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 15.05.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
ShowingAll content types

Forum discussions
Nexstim Receives NBS 6 Therapy System Order from New Customer in the United States Company Announcement, Helsinki, 3 July 2026 at 9 AM (EEST) Nexstim Receives NBS 6 Therapy System Order from New Customer in the United States Nexstim Plc (”Nexstim” or ”Company”) has received an order...
7/3/2026, 6:40 AM
by Kyhnykeisari
33
When summing up recent events, the signals suggest to me that something bigger is happening: A sudden large need for capital, even though there supposedly was no need. Relatively large insider investments. Completely new on this scale. Brainlab’s additional investment in Nexstim....
6/25/2026, 7:53 AM
by Jatast
24
First 10 min: The case discussed in the talk is “Michi,” who is quadriplegic following a moped accident and 50 surgeries 10 years ago. A chip was implanted in him in the summer of 2025; since October 2025, he has visited the clinic twice a week. Animated training videos are shown...
6/25/2026, 4:51 PM
21
New video released by Sinaptica
6/30/2026, 9:18 PM
by Kyhnykeisari
18
I interpret this trade announcement as wishing to emphasize a new client in a key market (USA) as well as the existing FDA approval for the treatment of depression.
7/3/2026, 7:13 AM
by KuplaSalkku
17
Research conducted to support the future: https://www.sciencedirect.com/science/article/pii/S1935861X26000823#sec5 The study indicates that neuronavigated TMS can potentially map much more than just traditional motor areas. In short: while traditional methods involve stimulating/...
6/25/2026, 8:52 AM
by AccionHombre
12
it is likely this article or similar: Voiko jopa muutamassa päivässä tehoava magneettistimulaatiohoito korvata psykoterapian? Kokenut psykiatri vastaa | Terveystalo
6/26/2026, 5:53 PM
by AccionHombre
8
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.8
2026

Interim report Q2'26

New NBS 6 system order for Nexstim from USA
Analyst Comment06.07.2026, 08.17 by
Atte Riikola

New NBS 6 system order for Nexstim from USA

This is a new customer for the company

Nexstim
Press release03.07.2026, 08.00

Nexstim Receives NBS 6 Therapy System Order from New Customer in the United States

Nexstim
Significant one-time order for Nexstim
Analyst Comment12.06.2026, 08.28 by
Antti Siltanen

Significant one-time order for Nexstim

The one-time order for ten systems strengthens our confidence in this year's growth estimates.

Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release11.06.2026, 08.00

Nexstim Receives Order for Ten NBS 6 Systems from Distributor

Nexstim
Nexstim received a new sales authorization for the NBS 6 system in Australia
Analyst Comment04.06.2026, 07.48 by
Antti Siltanen

Nexstim received a new sales authorization for the NBS 6 system in Australia

The sales authorization expands the use of the NBS 6 system to diagnostics and rehabilitation.

Nexstim
Press release03.06.2026, 09.00

Nexstim granted authorization for commercial distribution of NBS System 6 for use in diagnostics and post-operative rehabilitation in Australia

Nexstim
Regulatory press release25.05.2026, 08.00

Nexstim Plc’s New Shares Have Been Registered with the Finnish Trade Register

Nexstim
Regulatory press release18.05.2026, 16.00

Nexstim Plc: Disclosure of major holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim
Regulatory press release15.05.2026, 13.40

Nexstim Plc: Managers’ Transactions, Järnefelt

Nexstim
Regulatory press release15.05.2026, 13.40

Nexstim Plc: Managers’ Transactions, Hannula

Nexstim
Regulatory press release15.05.2026, 13.40

Nexstim Plc: Managers’ Transactions, Niemistö

Nexstim
Regulatory press release15.05.2026, 13.40

Nexstim Plc: Managers’ Transactions, Laine

Nexstim
Nexstim strengthens its balance sheet
Research15.05.2026, 08.00 by
Antti Siltanen

Nexstim strengthens its balance sheet

The 5 MEUR financing supports the growth strategy.

Nexstim
Regulatory press release13.05.2026, 16.00

Nexstim Plc: Managers’ Transactions, Hildén

Nexstim
Regulatory press release13.05.2026, 16.00

Nexstim Plc: Managers’ Transactions, Karvinen

Nexstim
Regulatory press release13.05.2026, 16.00

Nexstim Plc: Managers’ Transactions, Forss

Nexstim
Regulatory press release13.05.2026, 16.00

Nexstim Plc: Managers’ Transactions, Weckroth

Nexstim
Regulatory press release13.05.2026, 16.00

Nexstim Plc: Managers’ Transactions, Juokslahti

Nexstim
Regulatory press release13.05.2026, 14.00

Nexstim Plc: Disclosure of change in holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim
Regulatory press release13.05.2026, 08.05

Inside Information: Nexstim Plc Announces EUR 5 Million Investment from Eiffel and from Brainlab and Conversion of Options by Certain Option Holders

Nexstim